Opinion

Justin Taylor: We show that E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies.

Photo taken from: Justin Taylor/Twitter

Oct 10, 2023, 21:35

Justin Taylor: We show that E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies.

Justin Taylor, Assistant Professor at UM Sylvester Comprehensive Cancer Center and Principle Investigator at the Taylor Lab, made the following post on Twitter:

“Excited to see this paper in print Leukemia Journal! Many preclinical studies using RBM39 molecular glue degraders e.g indisulam. We show that E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies.

Great collaboration between Memorial Sloan Kettering Cancer Center and Sylvester Comprehensive Cancer Center! Led by twitter-less Drs. Jan Bewersdorf and Eytan Stein, Abdel Wahab Lab, Lu Lab, Namrata Chandhok, Justin Watts and many others. Access to the full text here.”

Source: Justin Taylor/Twitter

Abdel-Wahab Lab cancer Eytan Stein Jan Bewersdorf Justin Taylor Justin Watts Leukemia Journal Lu Lab Memorial Sloan Kettering Cancer Center Namrata Chandhok OncoDaily Oncology Sylvester Comprehensive Cancer Center

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage